SZodixStudyAcademic Library

Shelves Open access

Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated

Frank Xiaoqing Liu · Study

Home/Author

Frank Xiaoqing Liu

2 works· latest 2017· 1 institutionscluster: provisional

h-index2

i102

Citations208

Works here2

17

Most cited in this library

Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States2017 · 142 citations
Cost-Effectiveness of Pembrolizumab Versus Ipilimumab in Ipilimumab-Naïve Patients with Advanced Melanoma in the United States2017 · 66 citations

Works

2 shown

Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States

PharmacoEconomics·2017·6 authors·Open access

142citations

Cost-Effectiveness of Pembrolizumab Versus Ipilimumab in Ipilimumab-Naïve Patients with Advanced Melanoma in the United States

Journal of Managed Care & Specialty Pharmacy·2017·5 authors·Open access

66citations